Changeflow GovPing Healthcare & Life Sciences PDE6 Delta Inhibitors for Epilepsy and Neurodeg...
Routine Notice Added Final

PDE6 Delta Inhibitors for Epilepsy and Neurodegenerative Disorders, Remynd N.V., EP3634407A1

Favicon for changeflow.com EPO Patent Bulletin - Pharma (A61K)
Published
Detected
Email

Summary

The EPO published patent application EP3634407A1 disclosing PDE6 Delta inhibitors for the prevention and/or treatment of epilepsy and/or neurodegenerative disorders. The applicant is Remynd N.V. (inventors: Griffioen, Princen, Van Dooren, De Witte). The application has been classified under IPC A61K 31/422 and designated across 31 European states including DE, FR, GB, IT, NL, ES, PL, SE, and others. This A1 publication includes the search report and covers pharmaceutical compositions comprising PDE6 Delta inhibitors as active agents.

“INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS”

EPO , verbatim from source
Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 72 changes logged to date.

What changed

The EPO published patent application EP3634407A1 disclosing pharmaceutical compositions comprising PDE6 Delta inhibitors for use in preventing or treating epilepsy and/or neurodegenerative disorders. The application claims priority to IPC classifications A61K 31/422, A61K 45/00, A61P 25/08, and A61P 25/28.

For pharmaceutical companies and biotechnology firms engaged in CNS drug development, this patent publication signals competitive activity in the PDE6 Delta inhibitor space for neurological indications. R&D teams pursuing similar therapeutic approaches should review the claims for freedom-to-operate considerations and assess potential licensing opportunities with Remynd N.V.

Archived snapshot

Apr 25, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS

Publication EP3634407A1 Kind: A1 Apr 15, 2026

Applicants

Remynd N.V.

Inventors

GRIFFIOEN, Johan, Gerard, PRINCEN, Katrien, VAN DOOREN, Tom, François, L., DE WITTE, Koen

IPC Classifications

A61K 31/422 20060101AFI20181116BHEP A61K 45/00 20060101ALI20181116BHEP A61P 25/08 20060101ALI20181116BHEP A61P 25/28 20060101ALI20181116BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Notice
Branch
International
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3634407A1

Who this affects

Applies to
Pharmaceutical companies Medical device makers Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application filing Pharmaceutical research Drug development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!